2-DG in oncology
Repurposing rationale, anticancer evidence, clinical research patterns, safety and international access
Quick Jump Menu
5. Anticancer combinations and possible synergiesCombinations
2-DG + metformin: targeting two routes of cellular energy production
1. Overview
2-deoxy-D-glucose (2-DG) is an investigational glucose analogue studied to interfere with cancer-cell metabolism and increase sensitivity to other treatments. Human evidence is limited to early trials investigating safety, exposure and preliminary activity. These studies do not establish a survival benefit or a standard oncology regimen.
2. Drug-repurposing rationale
Many cancers increase glucose uptake and glycolysis to support growth. Hypoxic tumour regions may rely particularly heavily on glycolysis. Research explores whether 2-DG can exploit these vulnerabilities and increase sensitivity to radiation or chemotherapy.
The rationale includes metabolic stress, interference with protein processing, and reduced ability to tolerate treatment-induced damage. However, high glucose uptake alone does not establish sensitivity.
3. Mechanism of action
2-DG looks similar to glucose—the sugar cells use for energy—so cells take it in. Once inside, it becomes trapped in a form the cell cannot use normally. As it builds up, it makes it harder for the cell to use glucose for energy.
It can also interfere with how cells make and prepare proteins, causing stress inside the cell. In some laboratory studies, it also increases chemical stress that can damage cells. However, some cancer cells can adapt to these stressors and will use other fuels or recycle parts of themselves (Autophagy) to help them survive.
Rather than simply “starving cancer of sugar,” 2-DG creates several cellular stresses. Their anticancer effects depend on the model and exposure.
4. Evidence by cancer type
Preliminary evidence map. Laboratory findings do not establish patient benefit. Original cancer-specific papers require fuller extraction.
Cancer type | Evidence identified | Interpretation |
Glioma / glioblastoma | Historical early human studies combined oral 2-DG with large weekly radiation fractions; preclinical radio-sensitisation. [1,4] | Feasibility evidence; not established benefit with modern standard treatment. |
Prostate | Nine of 12 participants in a phase I study had castration-resistant prostate cancer. No PSA declines among seven completing therapy; three had prolonged radiographic stability. [2] | No control group; stability is not proof of treatment effect. |
Breast | Preclinical studies of metabolic inhibition, protein-processing effects and combinations. [1] | No breast-specific clinical regimen established by these sources. |
Non-small-cell lung | Preclinical paclitaxel/radiation research; one participant in the 12-person trial. [1,2] | Insufficient human evidence for lung-specific efficacy. |
Pancreatic | Preclinical 5-FU sensitisation and metabolic resistance research. [1] | Sensitivity is context-dependent; clinical benefit unestablished. |
Bladder | Selected cell models showed sensitisation to doxorubicin, cisplatin and gemcitabine, but not mitomycin C or 5-FU. [1] | Combination-specific effects, not universal synergy. |
Ovarian | Preclinical chemotherapy-combination research. [1] | Original papers need extraction before subtype-specific claims. |
Cervical | Preclinical radio-sensitisation; one participant in the 12-person trial. [1,2] | Insufficient clinical efficacy evidence. |
Osteosarcoma | Preclinical combinations with doxorubicin or paclitaxel. [2] | Not an established patient regimen. |
Mixed solid tumours: Raez et al. enrolled 34 patients. Best responses were stable disease in 11, partial response in one and progression in 22. This uncontrolled phase I study does not isolate the contribution of 2-DG from docetaxel.
5. Anticancer combinations and possible synergies
Combinations
Combination | Research findings | Clinical interpretation |
Radiation | Metabolic and oxidative stress may enhance treatment damage. Historical glioma protocols timed dosing near radiation. [1,4] | Cannot transfer historical schedules directly to modern protocols. |
Docetaxel | Studied in a 34-patient phase I trial; no pharmacokinetic interaction identified. [3] | Does not prove efficacy or absence of combined toxicity. |
Doxorubicin / paclitaxel | Enhanced activity in selected preclinical models. [2] | Clinical benefit unestablished. |
Cisplatin / gemcitabine / 5-FU | Sensitisation varies by cancer model and partner. [1] | No universal chemotherapy synergy. |
Autophagy inhibition | May block a protective metabolic response. [2] | Research strategy, not an established safe regimen. |
2-DG + metformin: targeting two routes of cellular energy production
Why researchers combine them
Cancer cells can change how they obtain energy. If a treatment interferes with one route, some cells can rely more heavily on another. This ability to adapt is one reason researchers study combinations that target different parts of cancer metabolism.
2-DG and metformin are studied together because they can interfere with two major routes that cells use to make ATP—the molecule that supplies energy for cellular activities:
Agent | Main action relevant to this combination | Intended contribution |
2-DG | Interferes with glycolysis, the breakdown of glucose in the main body of the cell. It also affects protein processing. | Makes it harder for the cell to rely on glucose metabolism. |
Metformin | Can inhibit mitochondrial respiration, including effects associated with complex I, part of the mitochondria’s energy-producing machinery. | Makes it harder for the cell to compensate through mitochondrial energy production. |
The aim is to put pressure on both energy routes at once, leaving cancer cells fewer opportunities to compensate. Neither drug should be described as reliably “switching off” its pathway in every patient or tumour. The strength of these effects depends on exposure and the cancer’s biology.
What happens when the combination works in research models?
In responsive models, the combination can lower ATP more strongly than either agent alone. The resulting energy shortage can activate AMPK, a cellular energy sensor, and affect pathways controlling growth and survival. Depending on the model, the consequences include slowed growth, cell-cycle arrest, autophagy or programmed cell death.
These are not necessarily steps in a single, inevitable chain. For example, one study associated cell death with sustained autophagy, while prostate-cancer research identified p53-dependent apoptosis. The response depends on the cell’s biological features.
What published studies have found
Research setting | Findings | Interpretation |
Prostate cancer cells — 2010 study | The combination inhibited mitochondrial respiration and glycolysis, depleted ATP and reduced viability more strongly than either treatment alone. The investigators reported 96% inhibition of viability in LNCaP cells, with a more moderate effect in normal prostate epithelial cells. Apoptosis involved AMPK and p53. | Supports the combination’s rationale in this laboratory setting. The response of normal cells does not establish whole-body safety in patients. |
Multiple preclinical cancer models — Cheong et al., 2011 | The combination decreased ATP, produced prolonged AMPK activation and cell death, and inhibited tumour growth in mouse xenografts. Restoring energy with methyl pyruvate reversed cell death, supporting energy deprivation as an important mechanism. | Evidence extends beyond one cell line, but remains preclinical. |
Triple-negative breast cancer cells — 2017 study | At 0.625 mM 2-DG and 2.5 micromolar metformin, viability fell by at least 72% in HCC1806 cells and 64% in MDA-MB-231 cells. | Relevant because it investigated relatively low metformin concentrations, but these are laboratory outcomes—not patient response rates. |
Triple-negative breast cancer cells — 2022 study | Effects depended on 2-DG concentration. With 5 mM metformin, total ATP production fell to approximately 75% of control at 0.6 mM 2-DG and 30% at 4.8 mM 2-DG. The study also investigated cell detachment and metabolic adaptation. | Shows why concentration and surviving-cell behaviour need attention, rather than assuming complete energy shutdown. |
Cervical, lung and colorectal cancer cells — 2026 study | Combined treatment reduced growth more effectively than single agents, with comparatively weaker effects on normal lung fibroblasts. Experiments used a wide concentration range, including millimolar metformin exposures. | Adds cancer-specific laboratory evidence, but does not establish a clinical regimen or safety across healthy tissues. |
Synergy: what should the report look for?
A combination producing a stronger effect than either agent alone is encouraging, but that finding does not automatically demonstrate synergy.
For each paper, the report should record whether the researchers formally assessed synergy, which method they used, and at what concentrations and treatment durations it occurred. Those details help distinguish a reproducible combination effect from a general statement that “two agents worked better than one.”
The studies above support investigation of dual metabolic targeting. They do not establish that every tumour will respond synergistically or that the same effect occurs at clinically tolerable exposure.
Does combining them allow lower doses?
Some experiments show substantial effects at lower concentrations of one agent when the other is present. This supports investigating whether combinations could reduce the exposure needed for an anticancer effect. However, it does not establish a lower, effective patient dose of 2-DG or a safer clinical schedule. Laboratory concentration, blood exposure and drug exposure inside a tumour are different measurements.
The report should therefore describe any dose-sparing finding precisely: which drug’s concentration was reduced, in which model, and whether formal comparisons demonstrated maintained activity.
What remains unresolved for patient treatment?
The papers summarised here provide cell and animal evidence—not a validated human 2-DG–metformin oncology protocol. They do not establish an effective dose pair, the best timing, survival benefit, or the safety of adding further agents.
For clinician discussions, the useful questions are:
Which evidence most closely matches this cancer type and subtype?
Does the proposed exposure resemble the exposure that produced the research effect?
Is the intention growth suppression, treatment sensitisation or cancer-cell killing?
What evidence supports giving the agents together rather than sequentially?
How will effectiveness and adverse effects be assessed?
If further agents are added, what does each contribute, and how will overlapping risks be reviewed?
Place within a broader combination approach
The rationale for this pairing is to address metabolic adaptation, not simply to add more substances. A clear combination plan should identify the purpose of each agent, the evidence supporting its inclusion, and the monitoring needed.
For 2-DG and metformin, the research supports a coherent dual-energy-targeting hypothesis and anticancer activity in several preclinical settings. Its translation into a dependable patient regimen remains a separate question requiring clinical evaluation.
6. Dosing, scheduling and treatment timing
The following are historical research exposures, not recommended doses. Do not merge these schedules into a patient protocol.
Study | Research schedule | Timing / safety context |
Stein et al., 2010 [2] | Oral 30, 45 or 60 mg/kg/day, days 1–14 of a 21-day cycle. Recommended phase II dose: 45 mg/kg/day. | One hour before breakfast. Grade 3 QTc prolongation in two patients at 60 mg/kg. |
Raez et al., 2013 [3] | Initially seven days every other week; later 21/28 days or continuous daily treatment. Selected tolerable dose: 63 mg/kg/day. | Docetaxel 30 mg/m² weekly, three of four weeks. Important toxicity in the 63–88 mg/kg range. |
Historical glioma programme [4] | Early protocol: oral 200 mg/kg before four weekly 5-Gy radiation fractions. | Approximately 20–30 minutes before radiation. Intermittent exposure differs from daily systemic dosing. |
Timing has several meanings: relation to food, relation to radiation or chemotherapy, days on/off treatment, and place in the disease pathway. A trial using pre-breakfast dosing does not establish benefits from fasting. No universal oncology schedule is established.
Exposure limitation: at 45 mg/kg, mean peak plasma concentration in the Stein study was approximately 449 micromolar (0.449 mM). Many laboratory experiments used millimolar concentrations, sometimes 5 mM or more. Blood and tumour concentrations differ, but this gap limits direct translation.
7. Safety and side-effect management
Reported symptoms included fatigue, sweating, dizziness and nausea. Symptoms resembling hypoglycaemia occurred, but reversible hyperglycaemia was also reported. Measured glucose is needed to interpret symptoms. QTc prolongation was dose-limiting in the single-agent trial and also occurred in the docetaxel trial; gastrointestinal bleeding was reported in the latter. [2,3]
The published adverse-event percentages in the Raez abstract concern the 63–88 mg/kg dose context and should not be treated as universal risk estimates. Small selected trials do not establish safety in all populations. Diabetes/glucose intolerance and several cardiac or neurological risks were exclusions in the Stein trial.
Agree a baseline and follow-up ECG/QTc plan, with electrolyte assessment and correction where needed. [2,6]
Plan glucose monitoring and assess symptoms alongside measurements.
Review hydration, nutrition, bleeding risk and overlapping treatment toxicity.
Document clinician-defined treatment-hold criteria, reassessment and urgent-care instructions.
Seek urgent assessment for fainting, significant palpitations, chest pain, seizure or suspected gastrointestinal bleeding. Some antiemetics themselves prolong QTc.
8. Safety and interaction issues
Issue | Interpretation |
QT-prolonging medicines | Cancer and supportive medicines may add cardiac risk; request pharmacist review. [6] |
Diabetes / glucose-lowering treatment | Glucose disturbances and trial exclusions create uncertainty; specialist review is needed. [2,3] |
Anticoagulants / bleeding | Bleeding in one trial and exclusions in another warrant assessment; not a proven interaction claim. [2,3] |
N-acetylcysteine / antioxidants | Laboratory effects were reduced by NAC. Best to avoid antioxidants that could rescue the stressed cancer cells. [1] |
Mannose | Reversed some glycosylation-related effects in laboratory models; clinical significance uncertain. [1] |
PET imaging | Competition with FDG can lower uptake without demonstrating tumour shrinkage. Inform the imaging team of exposure and timing. [2] |
There is no comprehensive validated oncology interaction list in these sources. Absence from an interaction checker is not evidence of safety.
9. International sourcing and access
Separate legality issue arise in the treatment country, product quality, and lawful continuity after returning home needs to be addressed.
Confirm exact compound and formulation: 2-DG is not interchangeable with a derivative.
Identify manufacturer and dispensing pharmacy; request identity, strength, quality, batch traceability and human-use documentation.
Discuss the basis for the cancer-specific combination and monitoring schedule.
Identify responsibility for adverse events and communication with the home oncology team.
Check prescriptions, travel documentation, customs rules and home-country import requirements.
Agree a plan for stopping treatment or returning home early.
The Stein trial used a controlled oral solution supplied by Threshold Pharmaceuticals. This does not establish equivalence with current commercial powders, capsules or solutions.
Country examples and limits
India: the official 2021 authorisation concerned emergency adjunctive COVID-19 use, not oncology. Current availability and oncology supply require separate verification.
Australia: unapproved-medicine pathways include Special Access Scheme, Authorised Prescriber arrangements, clinical trials and personal importation. Eligibility is individual and product-specific. Personal importation has conditions, including quantity limits and Australian prescription/authority requirements where applicable. An overseas prescription alone should not be assumed sufficient.
Other countries: regulator-specific research is still needed. Neither Australian nor US rules should be applied to members elsewhere. Access does not establish anticancer effectiveness.
Got something you want to add? Please use this: Feedback Form
References
[1] Pajak B et al. (2020). 2-Deoxy-d-Glucose and Its Analogs: From Diagnostic to Therapeutic Agents. International Journal of Molecular Sciences 21(1):234. https://doi.org/10.3390/ijms21010234
[2] Stein M et al. (2010). Targeting tumor metabolism with 2-deoxyglucose in patients with castrate-resistant prostate cancer and advanced malignancies. Prostate 70(13):1388–1394. https://pmc.ncbi.nlm.nih.gov/articles/PMC4142700/
[3] Raez LE et al. (2013). A phase I dose-escalation trial of 2-deoxy-D-glucose alone or combined with docetaxel in patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology 71:523–530. https://pubmed.ncbi.nlm.nih.gov/23228990/
[4] Dwarakanath BS et al. (2009). Targeting glucose metabolism with 2-deoxy-D-glucose for improving cancer therapy. Future Oncology. https://www.tandfonline.com/doi/full/10.2217/fon.09.44
[5] Government of India, Press Information Bureau (2021). Emergency adjunctive COVID-19 authorisation announcement. https://pib.gov.in/PressReleasePage.aspx?PRID=1717007&lang=en
[6] The QT interval prolongation potential of anticancer and antiemetic drugs: a review. Lancet Oncology (2022). https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(22)00221-2/fulltext
[7] Therapeutic Goods Administration. Unapproved therapeutic goods. https://www.tga.gov.au/products/unapproved-therapeutic-goods
[8] Therapeutic Goods Administration. Personal Importation Scheme. https://www.tga.gov.au/products/unapproved-therapeutic-goods/access-pathways/personal-importation-scheme
This information is for education only. It is not medical advice, diagnosis, or treatment. Please speak with a qualified clinician before making changes to care, medication, or supplement use.
© 2026 Abbey Mitchell. All rights reserved. Please share by URL rather than copying page text.